Wockhardt
 |
|
| Type | Public (NSE: WOCKPHARMA) |
|---|---|
| Industry | Pharmaceuticals Health care |
| Founded | 1960s |
| Founder(s) | Habil Khorakiwala |
| Headquarters | Mumbai, India |
| Area served | Worldwide |
| Key people | Habil Khorakiwala (Chairman) Murtaza Khorakiwala (Managing Director) Huzaifa Khorakiwala (Executive Director) |
| Products | Formulations Biopharmaceuticals Nutrition products Vaccines |
| Revenue |   4614 crore (US$840 million)[1] |
| Employees | 7,900 (2013) |
| Website | www.wockhardt.com |
Wockhardt Ltd. is a pharmaceutical and biotechnology company headquartered in Mumbai, India. The company has manufacturing plants in India, UK, Ireland, France and US, and subsidiaries in US, UK, Ireland and France. It is a global company with more than half of its revenue coming from Europe.[2][3] In 2011-2012 its UK and USA sales alone were US$475 million.[4] It has market presence in emerging markets such as Russia, Brazil, Mexico, Vietnam, Philippines, Nigeria, Kenya, Ghana, Tanzania, Uganda, Nepal, Myanmar, Sri Lanka, Mauritius, Lebanon and Kuwait.[5] The Company has a market capitalization of over 21100 crore (US$3.9 billion)[6] and an annual turnover of 3600 crore (US$660 million).[citation needed] It produces formulations, biopharmaceuticals, nutrition products, vaccines and active pharmaceutical ingredients (APIs).[7] The company employs over 7,900 people globally.[8] Wockhardt Hospitals is a subsidiary of the Wockhardt Group.[9]
Contents |
History [edit]
Wockhardt was founded by Habil Khorakiwala in the early 1960s.[8] His father Fakhruddin T. Khorakiwala had acquired Worli Chemical Works [10] in 1959. This was incorporated as Wockhardt Pvt. Ltd., in 1973.[2] Wockhardt Ltd. was incorporated on July 8.1999.[11] Wockhardt is often confused as a multinational because of its German sounding name.[12]
Wockhardt is the first company outside of the US and Europe to manufacture recombinant human insulin.[13]
Acquisitions and subsidiaries [edit]
Wockhardt's acquisitions include Wallis Laboratory, UK (1998), Merind, India (1998), CP Pharmaceuticals, UK (2003), Espharma GmbH, Germany (2004), Dumex India (2006), Pinewood Laboratory, Ireland (2006) and Negma, France (2007).[2] Wockhardt's debt following the acquisitions was close to Rs 3,800 crore, and Habil Khorakiwala quit as Managing Director.[14] The board of directors, on March 31, 2009 approved the appointments of Habil Khorakiwala's sons Murtaza Khorakiwala and Hozaifa Khorakiwala as Managing Director and Executive Director respectively.[15]
References [edit]
- ^ "Wockhardt:Fact Sheet". Wockhardt. Retrieved 2010-07-16.
- ^ a b c Sanju Verma, Amit Shah (2007). "Wockhardt : "Wock"ing the talk...". HDFC securities. India Research.
- ^ Wednesday, March 20, 2013. "Wockhardt set to join billion-dollar club". Business Standard. Retrieved 2013-03-20. Text " 11:45 AM IST " ignored (help)
- ^ "Who we are | Fact Sheet". Wockhardt. Retrieved 2013-03-20.
- ^ "Who we are | Overview". Wockhardt. Retrieved 2013-03-20.
- ^ "Wockhardt Ltd - Price, Fundamentals, Charts, Financials". Business Standard. Retrieved 2013-03-20.
- ^ "ABOUT US - Who We Are".
- ^ a b "ABOUT US".
- ^ "OUR OTHER WEBSITES".
- ^ Priyanka Sangani (March 28, 2008). "Marginal business logic". The Economic Times.
- ^ "Wockhardt Limited". Retrieved 2009-05-09.[dead link]
- ^ T. Surendar, Charles Assisi (January 19, 2008). "'We need a Nano for medicines too'". The Times of India.
- ^ "Introducing Wockhardt". Retrieved 2009-05-09.
- ^ Shobhana Subramanian (April 3, 2009). "Newsmaker: Habil F Khorakiwala, Scientist in a hurry". Business Standard.
- ^ "Murtaza Khorakiwala is new MD of Wockhardt, Hozaifa new Executive Director". DWS Pill Scribe. April 2, 2009.
